T Cell Targeted Strategies for Improved Efficacy and Safety of Specific Immunotherapy for Allergic Disease

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

T Cell Targeted Strategies for Improved Efficacy and Safety of Specific Immunotherapy for Allergic Disease

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 12(3): 201-222.

Author(s): Jennifer M. Rolland, Sara Prickett, Leanne M. Gardner and Robyn E O’Hehir.

Affiliation: Department of Immunology, AMREP, Monash University, Commercial Road, Melbourne, VIC. 3004. Australia.


Allergic diseases including asthma, rhinitis and eczema are known to be a major health and economic burden worldwide. Specific immunotherapy (SIT) is potentially curative but restricted in use, e.g. for asthmatics, due to risk of serious adverse events. Safer, effective SIT preparations require elucidation of mechanisms and immunoregulatory factors. Allergen-specific T cells play a pivotal role. For allergic individuals, allergen-stimulated T cells largely secrete IL-4, IL-5 and IL-13 (Th2-type cytokines), whereas non-allergics show predominant IFN-γ secretion (Th1-type). Clinically successful SIT is accompanied by altered allergen-specific T cell response, with decreased Th2/Th1 ratio, enhanced IL-10 secretion and regulatory T cell induction. Contributing factors include allergen concentration and form, adjuvant and antigen presenting cell type. In conventional SIT, high dose unfractionated allergen extracts are injected incrementally via the subcutaneous route. To avoid adverse IgE-mediated events but retain efficacy, hypoallergenic T cell-reactive allergen derivatives can be used. These include peptides containing dominant T cell epitopes of allergens, chemically-modified allergens, and recombinant whole or mutant allergens. Such approaches have been evaluated successfully in animal models and early phase clinical trials. Adjuvants and carriers including bacterial and viral components, liposomes and DNA vaccines also promote repolarisation of T cell response and regulatory T cell induction. However caution is needed as excessive IFN- γ secretion may invoke pathogenic inflammation. Sublingual administration has fewer adverse events and is gaining popularity for respiratory allergens, and other routes including intranasal and oral are under evaluation. T cell targeted strategies will facilitate wider clinical application of SIT and reliable laboratory assays for monitoring treatment.


Adjuvant, allergen, antigen presenting cell, DNA vaccine, immunotherapy, mutant allergen, regulatory T cell, T cell epitope peptide.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 12
Issue Number: 3
First Page: 201
Last Page: 222
Page Count: 22
DOI: 10.2174/18715230113129990011
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science